Your browser doesn't support javascript.
loading
DREADDs in Epilepsy Research: Network-Based Review.
Mueller, John-Sebastian; Tescarollo, Fabio Cesar; Sun, Hai.
Afiliación
  • Mueller JS; Department of Neurosurgery, Robert Wood Johnson Medical School, New Brunswick, NJ, United States.
  • Tescarollo FC; Department of Neurosurgery, Robert Wood Johnson Medical School, New Brunswick, NJ, United States.
  • Sun H; Department of Neurosurgery, Robert Wood Johnson Medical School, New Brunswick, NJ, United States.
Front Mol Neurosci ; 15: 863003, 2022.
Article en En | MEDLINE | ID: mdl-35465094
ABSTRACT
Epilepsy can be interpreted as altered brain rhythms from overexcitation or insufficient inhibition. Chemogenetic tools have revolutionized neuroscience research because they allow "on demand" excitation or inhibition of neurons with high cellular specificity. Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are the most frequently used chemogenetic techniques in epilepsy research. These engineered muscarinic receptors allow researchers to excite or inhibit targeted neurons with exogenous ligands. As a result, DREADDs have been applied to investigate the underlying cellular and network mechanisms of epilepsy. Here, we review the existing literature that has applied DREADDs to understand the pathophysiology of epilepsy. The aim of this review is to provide a general introduction to DREADDs with a focus on summarizing the current main findings in experimental epilepsy research using these techniques. Furthermore, we explore how DREADDs may be applied therapeutically as highly innovative treatments for epilepsy.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Mol Neurosci Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Mol Neurosci Año: 2022 Tipo del documento: Article